Cite
HARVARD Citation
Herbst, R. et al. (n.d.). O81 IMpower110: interim overall survival (OS) analysis of a phase III study of atezolizumab (ATEZO) monotherapy vs platinum-based chemotherapy (CHEMO) as first-line (1L) treatment in PD-L1–selected NSCLC. Journal for immunotherapy of cancer. p. A1. [Online].